Skip to main content

Table 4 Correlations between TILs and pCR in clinicopathologic subgroups

From: Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

Variable No. of patients Per 10% sTILs increase Per 10% iTILs increase
Adjusted OR 95% CI P-value* Adjusted OR 95% CI P-value*
Age (years)
  < 50 80 1.06 1.01–1.11 0.78 1.09 1.01–1.18 0.64
  ≥ 50 86 1.07 1.02–1.12 1.12 1.03–1.22
Tumor size (cm)
  ≤ 2 22 1.05 0.99–1.12 0.68 1.07 0.92–1.25 0.72
 2–5 115 1.06 1.02–1.10 1.09 1.02–1.16
  > 5 29 1.11 1.00–1.24 1.16 1.00–1.35
Lymph node status
 Negative 53 1.07 1.00–1.14 0.81 1.07 0.96–1.18 0.56
 Positive 113 1.06 1.02–1.10 1.11 1.04–1.19
Grade
 2 31 1.01 0.90–1.13 0.34 1.02 0.84–1.23 0.46
 3 135 1.07 1.03–1.10 1.11 1.04–1.17
LVI
 Negative 130 1.06 1.02–1.10 0.49 1.08 1.02–1.15 0.84
 Positive 36 1.14 0.93–1.39 1.11 0.83–1.48
NAC
 Anthracycline + paclitaxel 136 1.07 1.03–1.12 0.23 1.12 1.06–1.20 0.14
 Paclitaxel + platinum 30 1.01 0.93–1.10 1.00 0.87–1.14
  1. Abbreviations: pCR pathological complete response, sTILs stromal tumor-infiltrating lymphocytes, iTILs intratumoral tumor-infiltrating lymphocytes, LVI lymphovascular invasion, NAC neoadjuvant chemotherapy, OR odds ratio, 95% CI 95% confidence interval
  2. *The chi-squared test